Sanofi Appealing Findings In Review Of Zantac 360 Doctor-Recommended Claims Challenged By J&J
Now Competing In Famotidine Category, Zantac 360 Used Doctors' Survey To Differentiate
Executive Summary
French pharma disagrees with NAD finding, following review of a claims made in online and social media ads, retailers' websites and a TV commercial, that the claim “#1 doctor recommended medicine” for Zantac 360 refers to the brand and not famotidine, also used in other OTC heartburn remedies, including Pepcid.
You may also be interested in...
Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient
Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.
Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine
Along with its Q1 results including a 7.3% drop in consumer health sales to €1.11bn ($1.35bn), Sanofi announces 10-mg famotidine tablets branded Zantac 360° will be available in the US in June.
US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.